Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Transfus Apher Sci. 2021 Aug;60(4):103148. doi: 10.1016/j.transci.2021.103148. Epub 2021 Apr 24.
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first seen in the city of Wuhan, China, in December 2019 and then spread worldwide. On 24 March 2020, the U.S. Food and Drug Administration reported that the use of convalescent plasma (CP) containing antibodies against COVID-19 could be effective against infection. The aim of this study is to retrospectively investigate whether early CP transfusion treatment has an effect on recovery of clinical and laboratory parameters in patients diagnosed with severe COVID-19 who were admitted to the intensive care unit (ICU). The study included 141 consecutive patients who had laboratory confirmation of COVID-19 and were admitted to the ICU between 1 May and 30 September 2020. Of the 141 patients, 84 received CP in the first five days of hospitalization in the ICU (early group), and 57 received CP after the fifth day of hospitalization in the ICU (late group). There were no significant differences between the two groups in terms of age, gender, comorbidities and the severity of the disease (according to the evaluation of lung tomography). There was no difference between the two groups in terms of mechanical ventilator needed, inotrope support, and tracheostomy procedure during the ICU admission (p = 0.962, p = 0.680, and p = 0.927, respectively). Despite these limitations, the overriding result of our study is that it suggests that administration of CP either early or late in the treatment of COVID-19, had no effect on mortality.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的大流行于 2019 年 12 月在中国武汉市首次出现，随后在全球范围内传播。2020 年 3 月 24 日，美国食品和药物管理局报告称，使用含有针对 COVID-19 的抗体的恢复期血浆（CP）可能对感染有效。本研究旨在回顾性调查在因 COVID-19 而入住重症监护病房（ICU）的重症患者中，早期 CP 输注治疗是否对临床和实验室参数的恢复有影响。该研究纳入了 2020 年 5 月 1 日至 9 月 30 日期间在 ICU 住院并经实验室确认患有 COVID-19 的 141 例连续患者。在这 141 例患者中，84 例在 ICU 住院的前 5 天内接受 CP（早期组），57 例在 ICU 住院的第 5 天后接受 CP（晚期组）。两组患者在年龄、性别、合并症和疾病严重程度（根据肺部 CT 评估）方面无显著差异。两组在 ICU 入住期间所需的机械通气、正性肌力支持和气管切开术方面无差异（p=0.962、p=0.680 和 p=0.927）。尽管存在这些局限性，我们的研究结果表明，COVID-19 患者早期或晚期接受 CP 治疗对死亡率没有影响。
